Objective.To analyze the course and outcomes of pregnancies in women at high risk of fetal chro-mosomal abnormalities, preeclampsia, fetal growth retardation, and preterm birth according to the results of prenatal screening. Patients and methods. This prospective study included 443 women with singleton pregnancies. Study participants were divided into two groups: Group 1 included women at high risk of complica-tions (n = 235), while Group 2 (control) comprised women at low risk of gestational complications (n = 208). Patients in Group 1 were further subdivided into 4 subgroups: subgroup 1A included women at risk of fetal chromosomal abnormalities (CA) (n = 69); subgroup 1B included women at risk of preeclampsia (PE) (n = 66); subgroup 1C included women at risk of fetal growth retardation (FGR) (n = 48); and subgroup 1D included women at risk of preterm birth (PB) (n = 52). Confirmed chromosomal abnormalities were considered as an exclusion criterion. Results. Threatened miscarriage (TM) and bleeding in the first trimester were significantly more common in patients from Group 1. In the second trimester, the risk of TM was increased among women from subgroups 1A, 1B, 1C, and particularly 1D. In the third trimester, we observed sig-nificant differences in the frequency of FGR between group 1 (subgroups 1A, 1С, 1D) and controls. In subgroups 1A, 1B, 1C, and 1D, the incidence of PE and FGR was higher in patients who did not receive aspirin. The frequency of threatened PB was higher in subgroups 1B, 1C, and 1D compared to Group 2 (p < 0.05). Conclusion. High prenatal risk of fetal CA should be considered as a risk factor for PB, TM, FGR, and PE. Key words: prenatal screening, chromosomal abnormalities, preeclampsia, fetal growth retarda-tion, preterm birth, pregnancy, perinatal risk
Effect of maternal factors on indicators of increased risk of chromosomal abnormalities (CA), pre-eclampsia (PE), Small-forGestational-Age Fetus (SGA fetus) and preterm labour and birth (PB) during prenatal screening has not been sufficiently studied. Aim. To study the effect of maternal reproductive factors on the risk indicators of CA, PE, SGA fetus and PB, assessed during prenatal screening using the Astraia Obstetrics module. Materials and methods. Of the 11,841 pregnant women who were prenatal screened, 18.53% of the patients had at high risk of the outcomes studied (frequency 1: 100 and above). The subgroup of isolated high risk for CA included 69, PE — 66, SGA fetus — 48, PB — 52 patients. From the group of patients with low risk, 208 patients were selected for the control group by the method of stratified randomization by age. Results. Among extragenital diseases, the most common in all high-risk subgroups were: hypertension (AH) I and II degree — 31–47% versus 4.8% of the control group (p < 0.05), varicose veins of the lower extremities (VVLE) — 17–30% vs. 5.3% in the control group (p < 0.05), a history of ovarian tumor — 12–33% vs. 3% in the control group (p < 0.05). In the high-risk subgroups for the development of CA, PE and SGA fetus, fibroids uterus and iron deficiency anaemia (IDA) were more common compared to control: 10–41% vs. 1% (p < 0.05) and 10–17% vs. 3% (p < 0.05), respectively (p < 0.05). Primiparas with a history of pregnancy were more common in subgroups with a high risk of CA (33%) and PR (35%) versus 17% in controls. Conclusion. An association has been established between high risk for all the outcomes studied and AC, VVLE, history of ovarian tumor. High-risk subgroups for CA, PE and SGA fetus have a higher incidence of uterine fibroids and IDA compared to control.
AIM: We aimed at assessing the status of newborns in the early neonatal period in a group of mothers at high prenatal risk for preeclampsia (PE), fetal growth restriction (FGR), preterm birth (PTB), and fetal chromosomal abnormalities (FCA). MATERIALS AND METHODS: We prospectively analyzed the status of 435 singletons. Mothers in the first-trimester underwent prenatal screening with risk assessment. Group 1 (study group, n=231) included high-risk subgroups for FCA (subgroup 1A, n=67), maternal PE (subgroup 1B, n=66), FGR (subgroup 1C, n=46), and PTB (subgroup 1D, n=52). We excluded risk combinations. Group 2 (controls) included 204 children of low-risk women. RESULTS: Group 1 had a higher incidence of mild-to-moderate asphyxia compared with group 2 (p 0.05) and was more frequent in 1B, 1C, and 1D subgroups. Moreover, the frequency of severe asphyxia was similar between the groups (p 0.05). Intrauterine growth restriction (IUGR) and developmental delay were more frequent in group 1 than in group 2 (p 0.05). Moreover, group 1 children required monitoring and treatment more frequently that in group 2 (p 0.05). The frequency of infectious complications in group 1 and 1A, 1B, and 1C subgroups was equally higher than that of group 2 (p 0.05), while respiratory distress syndrome predominated in group 1 (subgroup 1D) and was not observed in group 2. The discharge rate was 95.7% in group 1 and 84.0% in group 2 (p 0.05). On days 3 to 5, 16% and 3.4% of children in groups 1 and 2, respectively, were transferred to the second stage of aftercare (p 0.05). CONCLUSIONS: In the early neonatal period, children born to high-risk mothers, as opposed to those born to low-risk mothers, were significantly more likely to have asphyxia, IUGR, infectious complications, and indications for continued treatment in the second stage of nursing.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.